A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Single Ascending Dose Administration to Healthy Male Subjects With Elevated LDL-C Levels
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
At a glance
- Drugs AZD-8233 (Primary)
- Indications Hypercholesterolaemia; Metabolic disorders
- Focus Adverse reactions; Biomarker; First in man
- Sponsors AstraZeneca
- 24 Sep 2018 Planned End Date changed from 10 Jul 2019 to 23 Jul 2019.
- 24 Sep 2018 Planned primary completion date changed from 10 Jul 2019 to 23 Jul 2019.
- 17 Aug 2018 Status changed from not yet recruiting to recruiting.